NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS Russian patent published in 2010 - IPC C07D265/36 C07D413/04 C07D279/16 A61K31/5415 A61K31/538 

FIELD: medicine, pharmaceutics.

SUBSTANCE: there is described a compound of formula [I]: where A cycle represents a benzene cycle optionally having substitute(s) different from R¹, R¹ represents a group of formula R^aSO₂NH-, R^aSO₂NH-CH₂- or (R^b)(R^c)NSO_2-, R^a represents C₁-C₆ alkyl group, C₃-C₁₀cycloalkyl group, an amino group, 6-10-member monocyclic or bicyclic aryl group or 5-10-member monocyclic or bicyclic heteroaryl group containing 1-2 heteroatoms, chosen from oxygen, sulphur and nitrogen atoms, R^b and R^c are identical or different, and each represents hydrogen atom, C₁-C₆alkyl group or C₃-C₁₀cycloalkyl group, one of R² and R³ represents hydrogen atom, halogen atom or C₁-C₆alkyl group, and the other represents hydrogen atom, C₁-C₆alkyl group, C₁-C₆alkoxycarbonyl group or phenyl group, or both are combined with each other together with the neighbouring carbon atom to form C₃-C₁₀cycloalkyl group, X represents oxygen atom, sulphur atom, or formula group of -NR⁴-; Y represents a group of formula -C(=O)-, -C(=S)- or CH(R⁵)-; Ar represents optionally substituted 6-10-member monocyclic or bicyclic aryl group or 5-10-member monocyclic or bicyclic group; Q represents a simple bond, C₁-C₆alkylene group or C₂-C₆alkenylene group, or its pharmaceutically acceptable salts There are described specific compounds of formula [I], and also intermediate compounds.

EFFECT: presented compounds exhibit affinity to mineralocorticoid receptor (MR) and are applicable for prevention or treatment of various diseases or diseased states associated with such receptor.

11 cl, 54 tbl, 410 ex